Combined treatment by pentoxifylline and tocopherol for recipient women with a thin endometrium enrolled in an oocyte donation programme.
BACKGROUND
To evaluate the effect of an antifibrotic treatment by a combination of pentoxifylline (PTX) and tocopherol (vitamin E) in patients with a thin endometrium who were enrolled in an oocyte donation programme.


METHODS
Eighteen oocyte recipients who failed to develop a pre-ovulatory endometrial thickness of at least 6 mm after receiving vaginal micronized estradiol were enrolled in the study. The patients received a combination of PTX (800 mg/day) and vitamin E (1000 IU/day) for 6 months. The main outcome measurements were the change in endometrial thickness and the pregnancy and delivery rates after treatment.


RESULTS
Endometrial thickness increased significantly (P <0.001), with a mean of (+/-SD) 4.9 +/-0.6 mm before and 6.2 +/- 1.4 mm after treatment, with 72% (13/18) of patients being good responders. Five patients either did not respond to the treatment or responded only slightly. Three patients, of which two had received previous radiotherapy, became spontaneously pregnant, and two became pregnant after embryo transfer. Three patients did not have embryo transfer. A total of four babies were delivered. The pregnancy rate was thus 33% and the delivery rate 27%.


CONCLUSIONS
Treatment by combination of PTX and vitamin E appears to improve the pregnancy rate in patients with a thin endometrium by increasing the endometrial thickness and improving ovarian function. This was especially noticeable in patients who had previously received total body irradiation.
Lédée-Bataille
N
N
INSERM U131, Hôpital Antoine Béclère, Clamart, France. Ledeenathalie@aol.com
Olivennes
F
F
Lefaix
J-L
JL
Chaouat
G
G
Frydman
R
R
Delanian
S
S
D000328:Adult; D001723:Birth Rate; D004359:Drug Therapy, Combination; D004717:Endometrium / Q000000981:diagnostic imaging* / Q000187:drug effects*; D005260:Female; D005355:Fibrosis / Q000517:prevention & control; D006801:Humans; D018587:Oocyte Donation; D010049:Ovarian Diseases / Q000517:prevention & control*; D010431:Pentoxifylline / Q000627:therapeutic use*; D011247:Pregnancy; D018873:Pregnancy Rate; D024505:Tocopherols / Q000627:therapeutic use*; D014463:Ultrasonography
D024505:Tocopherols; D010431:Pentoxifylline